Showing 61 to 72 of 79 results
Promising Phase 1 Results for Personalized Kidney Cancer Vaccine NeoVax
A phase 1 trial of NeoVax, a personalized cancer vaccine for kidney cancer, showed promising results in 9 patients, with all remaining disease-free after nearly three years; the vaccine induced a significant increase in T cells, highlighting its potential to prevent recurrence.
Promising Phase 1 Results for Personalized Kidney Cancer Vaccine NeoVax
A phase 1 trial of NeoVax, a personalized cancer vaccine for kidney cancer, showed promising results in 9 patients, with all remaining disease-free after nearly three years; the vaccine induced a significant increase in T cells, highlighting its potential to prevent recurrence.
Progress
40% Bias Score
Phase One Clinical Trial Begins for Novel Russian Oncolytic Virus Cocktail
The Herzen Institute in Moscow has begun phase one clinical trials of a new Russian-made oncolytic virus cocktail for breast cancer treatment, involving 38 patients and showing promise in pre-clinical trials, with plans to expand to glioblastoma and other cancer types in later phases.
Phase One Clinical Trial Begins for Novel Russian Oncolytic Virus Cocktail
The Herzen Institute in Moscow has begun phase one clinical trials of a new Russian-made oncolytic virus cocktail for breast cancer treatment, involving 38 patients and showing promise in pre-clinical trials, with plans to expand to glioblastoma and other cancer types in later phases.
Progress
56% Bias Score
Personalized Cancer Vaccine Shows Promising Results in Kidney Cancer Trial
A phase I trial at Dana-Farber Cancer Institute showed that a personalized cancer vaccine kept nine kidney cancer patients cancer-free for three years post-treatment; this is a significant advancement given the high recurrence rate of kidney cancer.
Personalized Cancer Vaccine Shows Promising Results in Kidney Cancer Trial
A phase I trial at Dana-Farber Cancer Institute showed that a personalized cancer vaccine kept nine kidney cancer patients cancer-free for three years post-treatment; this is a significant advancement given the high recurrence rate of kidney cancer.
Progress
40% Bias Score
CD74 Protein Identified as Potential Biomarker for Colorectal Cancer Immunotherapy Response
Researchers have identified the protein CD74 as a potential biomarker to predict immunotherapy response in colorectal cancer patients, improving treatment selection and potentially expanding access to immunotherapy.
CD74 Protein Identified as Potential Biomarker for Colorectal Cancer Immunotherapy Response
Researchers have identified the protein CD74 as a potential biomarker to predict immunotherapy response in colorectal cancer patients, improving treatment selection and potentially expanding access to immunotherapy.
Progress
44% Bias Score
CAR T-cell Therapy for Breast Cancer: Early Trials Show Promise, but Challenges Remain
Currently, 16 active phase I/II clinical trials are investigating CAR T-cell therapy for various solid tumors, including breast cancer, primarily in the US, focusing on safety and feasibility; results are preliminary, showing some encouraging but limited data, with no phase III trials yet.
CAR T-cell Therapy for Breast Cancer: Early Trials Show Promise, but Challenges Remain
Currently, 16 active phase I/II clinical trials are investigating CAR T-cell therapy for various solid tumors, including breast cancer, primarily in the US, focusing on safety and feasibility; results are preliminary, showing some encouraging but limited data, with no phase III trials yet.
Progress
40% Bias Score
CAR T-Cell Therapy Shows Promise for Autoimmune Disease Cure
UK scientists are trialing CAR T-cell therapy—a cancer treatment—to cure autoimmune disorders like lupus, with early results showing potential for remission and prevention, although long-term effects are still unknown.
CAR T-Cell Therapy Shows Promise for Autoimmune Disease Cure
UK scientists are trialing CAR T-cell therapy—a cancer treatment—to cure autoimmune disorders like lupus, with early results showing potential for remission and prevention, although long-term effects are still unknown.
Progress
56% Bias Score
Personalized Cancer Vaccine Shows Promise in Treating Advanced Kidney Cancer
A new personalized cancer vaccine shows promise in treating advanced kidney cancer; in a small study, nine patients with stage 3 or 4 kidney cancer remained cancer-free for an average of 34.7 months after receiving a vaccine tailored to their specific tumor type, triggering a significant immune resp...
Personalized Cancer Vaccine Shows Promise in Treating Advanced Kidney Cancer
A new personalized cancer vaccine shows promise in treating advanced kidney cancer; in a small study, nine patients with stage 3 or 4 kidney cancer remained cancer-free for an average of 34.7 months after receiving a vaccine tailored to their specific tumor type, triggering a significant immune resp...
Progress
40% Bias Score
Personalized Cancer Vaccine Shows Promise in Advanced Kidney Cancer
A small study of nine patients with advanced kidney cancer showed promising results using a personalized vaccine targeting neoantigens; after three years, all patients remained cancer-free, suggesting a new approach to treating this challenging disease.
Personalized Cancer Vaccine Shows Promise in Advanced Kidney Cancer
A small study of nine patients with advanced kidney cancer showed promising results using a personalized vaccine targeting neoantigens; after three years, all patients remained cancer-free, suggesting a new approach to treating this challenging disease.
Progress
44% Bias Score
OSE Immunotherapeutics Launches Global Phase 3 Trial for Cancer Vaccine
OSE Immunotherapeutics, a French biotech firm, launched a global Phase 3 trial for its cancer vaccine Tedopi, securing \$9.3 million in public funding and partnerships with AbbVie and Boehringer Ingelheim, resulting in a 66% stock increase over the past year.
OSE Immunotherapeutics Launches Global Phase 3 Trial for Cancer Vaccine
OSE Immunotherapeutics, a French biotech firm, launched a global Phase 3 trial for its cancer vaccine Tedopi, securing \$9.3 million in public funding and partnerships with AbbVie and Boehringer Ingelheim, resulting in a 66% stock increase over the past year.
Progress
48% Bias Score
Modified Bird Virus Shows Promise in Treating Multiple Cancers
A Chinese study showed a modified bird virus, NDV-GT, shrunk or stopped tumor growth in 22 of 23 patients with eight different advanced cancers in a trial; further trials are planned.
Modified Bird Virus Shows Promise in Treating Multiple Cancers
A Chinese study showed a modified bird virus, NDV-GT, shrunk or stopped tumor growth in 22 of 23 patients with eight different advanced cancers in a trial; further trials are planned.
Progress
40% Bias Score
Shared Neoantigens in Endometrial Cancers Suggest Potential for Nous-209 Vaccine
An Italian study found that endometrial cancers with mismatch repair deficiency share many neoantigens with colon and stomach cancers, suggesting the potential use of the existing Nous-209 therapeutic vaccine; 80% of 35 patients showed at least one neoantigen present in Nous-209.
Shared Neoantigens in Endometrial Cancers Suggest Potential for Nous-209 Vaccine
An Italian study found that endometrial cancers with mismatch repair deficiency share many neoantigens with colon and stomach cancers, suggesting the potential use of the existing Nous-209 therapeutic vaccine; 80% of 35 patients showed at least one neoantigen present in Nous-209.
Progress
20% Bias Score
Johnson & Johnson Targets Autoimmune Diseases with Novel Therapies
Johnson & Johnson, a leader in immunology, is researching treatments for over 80 autoimmune and alloantibody diseases affecting nearly 240 million globally, focusing on three segments with a targeted approach to lower pathogenic IgG antibodies while preserving overall immune function, addressing a c...
Johnson & Johnson Targets Autoimmune Diseases with Novel Therapies
Johnson & Johnson, a leader in immunology, is researching treatments for over 80 autoimmune and alloantibody diseases affecting nearly 240 million globally, focusing on three segments with a targeted approach to lower pathogenic IgG antibodies while preserving overall immune function, addressing a c...
Progress
36% Bias Score
Showing 61 to 72 of 79 results